Beauty

Shiseido to Sell Aupres Owner SLC to IDG-Led Consortium

The binding deal covers the Chinese subsidiary, its Beijing factory and a transition support package as Shiseido redirects resources to priority brands.

Dalia MansourNovember 19, 20265 min read0 views
A frosted-glass cosmetic bottle and a small factory model sit on a polished desk beside a portfolio grid, linked by a handover path over an abstract map.

Shiseido has agreed to sell Shiseido Liyuan Cosmetics (SLC), the Chinese subsidiary that makes and sells the Aupres brand, to a consortium led by Hong Kong-headquartered private equity firm IDG Capital. The Japanese cosmetics group signed a binding agreement to transfer the entire company; financial terms were not disclosed.

The transaction is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China. Under the deal, funds managed by IDG Capital will hold 95% of the equity through two special purpose vehicles. A limited partnership established mainly by SLC’s new management team will hold the remaining 5%.

The sale includes SLC’s Beijing factory and production equipment. Shiseido said it believes independent operation under IDG will support SLC’s sustainable growth and brand value. To ease the handover, Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, it will also provide support for new product development, technical assistance for stable supply of existing products, and continued supply of raw materials and selected products. The arrangement aims to help maintain SLC’s innovation capabilities, product quality and business continuity.

Joint venture history

SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group, which is owned by the Beijing Municipal Government. The company has sold the C-beauty brand Aupres since 1994. With the joint venture agreement due to expire in December 2026, the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan’s 35% stake, giving it full ownership before the sale.

Profitability and China focus

The divestment is part of Shiseido’s effort to improve profitability and capital efficiency under its 2030 Medium-Term Strategy. The group said it wants to drive sustainable growth and strengthen its competitiveness in China by concentrating management resources on areas where it enjoys the greatest competitive advantage. Shiseido described the China subsidiary as a business that requires continued investment in product innovation and digital capabilities, and said the sale will allow it to focus on priority brands and higher-growth opportunities.

Shiseido also called China a strategically important and attractive, dynamic market, where the competitive landscape continues to evolve amid rapid e-commerce expansion, changing consumer behavior and the emergence of diverse market participants.

Financial backdrop

The divestment comes days after Shiseido reported a 124.3% jump in core operating profit for the third quarter of 2026, to ¥67.5 billion, or US$422.13 million. The company attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales grew 0.7%. Shiseido raised its full-year core operating profit forecast from ¥59 billion, or US$433 million, to ¥87 billion, or US$546 million, following those results.